Monday, November 25, 2024
spot_img
spot_img
HomeNewsBusiness WireGlobal Pulmonary Tuberculosis Clinical Trials Research Report 2022 - ResearchAndMarkets.com

Global Pulmonary Tuberculosis Clinical Trials Research Report 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Pulmonary Tuberculosis – Global Clinical Trials Review, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.

This clinical trial report provides an overview of Pulmonary Tuberculosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Pulmonary Tuberculosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Key Topics Covered:

  • Report Guidance
  • Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Pulmonary Tuberculosis to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Pulmonary Tuberculosis to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Pulmonary Tuberculosis Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix

Companies Mentioned

  • Johnson & Johnson
  • Otsuka Holdings Co Ltd
  • Pharmasyntez
  • Sanofi
  • IQVIA Holdings Inc
  • Cadila Pharmaceuticals Ltd
  • GlaxoSmithKline Plc
  • LegoChem Biosciences Inc
  • Medecins Sans Frontieres
  • Sequella Inc

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/h7itt8

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

spot_img
RELATED ARTICLES
spot_img
spot_img
spot_img

Caribbean News

Chile’s economy bounces back in the third quarter

By FocusEconomics GDP reading: GDP increased 0.7 percent on a seasonally adjusted quarter-on-quarter basis in the third quarter, contrasting the 0.6 percent contraction recorded in the...

Global News